Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06572839 · ClinicalTrials.gov registry record · NA

Amnio-Maxx in Patients With Diabetic Foot Ulcers Unresponsive to Standard of Care Treatment Alone

A NA study of Diabetic Foot Ulcer, sponsored by Capsicure.

Recruiting
Registry status
NA
Development phase
150
Enrollment target
12
Study locations

NCT06572839 is a NA study of Diabetic Foot Ulcer that is actively recruiting participants, run by Capsicure. The registered enrollment target is 150 participants, below the 253-participant average among 67 other Diabetic Foot Ulcer trials with a reported enrollment target (41% lower). The trial reports 12 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06572839, a NA study of Diabetic Foot Ulcer, is actively recruiting participants, sponsored by Capsicure.

RECRUITING
Registry status
NA
Development phase
150 participants
Enrollment target
12
Study locations

Study Summary

This randomized controlled study evaluates the adjuvant use of Amnio-Maxx in patients with diabetic foot ulcers

Conditions Studied

Interventions

  • OTHER Amnio-Maxx

Study Locations (12)

Florida

  • Solutions Medical Research - Coral Gables
  • Evolution Research Center - Hialeah
  • Symphony Research - Jacksonville
  • Quality Care Clinical Research - Miami

Texas

  • Stride Clinical Research - Houston
  • Ten20 Medical - Sunnyvale

Alabama

  • North Alabama Research Center, LLC - Athens

California

  • North Park Podiatry - San Diego

Louisiana

  • Medcentris - Hammond

New Jersey

  • Curalta Clinical Trials - Oradell

New York

  • Suffolk Foot and Ankle - East Patchogue

Pennsylvania

  • PA Foot and Ankle Associates - Allentown

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2024-10-25
Est. Completion 2025-10-31
Phase NA

Sponsor

Capsicure

3 total trials

What the Registry Record Tells You About NCT06572839

The ClinicalTrials.gov registry entry for NCT06572839 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 253-participant average among 67 other Diabetic Foot Ulcer trials with a reported enrollment target (41% lower). The listed sponsor is Capsicure, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Diabetic Foot Ulcer appearing as the primary indexed condition, and to 1 intervention - of which Amnio-Maxx is the first listed.

NCT06572839 reports 12 study locations spanning 8 distinct geographic areas - top geographies include Florida, Texas, Alabama.

Frequently Asked Questions

What is clinical trial NCT06572839 about?

NCT06572839 is a clinical study titled "Amnio-Maxx in Patients With Diabetic Foot Ulcers Unresponsive to Standard of Care Treatment Alone". This randomized controlled study evaluates the adjuvant use of Amnio-Maxx in patients with diabetic foot ulcers

What is the current status of trial NCT06572839?

This trial is currently recruiting. It is a NA study. The enrollment target is 150 participants. The study started on 2024-10-25. Estimated completion is 2025-10-31.

What conditions does trial NCT06572839 study?

This clinical trial studies the following conditions: Diabetic Foot Ulcer.

What interventions are being tested in trial NCT06572839?

The interventions under investigation include: Amnio-Maxx (OTHER).

Who is sponsoring clinical trial NCT06572839?

This trial is sponsored by Capsicure, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06572839 being conducted?

This trial has 12 study locations across Alabama, California, Florida, Louisiana, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Diabetic Foot Ulcer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.